Do analysts prefer SHPH or CVKD?

Cadrenal Therapeutics has a consensus price target of $13.00, indicating a potential upside of 501.85%. Given Cadrenal Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Cadrenal Therapeutics is more favorable than Shuttle Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Shuttle Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cadrenal Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings and valuation, SHPH or CVKD?

Cadrenal Therapeutics is trading at a lower price-to-earnings ratio than Shuttle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Shuttle Pharmaceuticals N/A N/A -$11.72M -$47.70 N/A Cadrenal Therapeutics N/A N/A -$13.24M -$5.63 N/A

Is SHPH or CVKD more profitable?

Shuttle Pharmaceuticals' return on equity of -408.34% beat Cadrenal Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Shuttle Pharmaceuticals N/A -408.34% -138.15% Cadrenal Therapeutics N/A -411.03% -275.61%

Does the media favor SHPH or CVKD?

In the previous week, Shuttle Pharmaceuticals had 2 more articles in the media than Cadrenal Therapeutics. MarketBeat recorded 6 mentions for Shuttle Pharmaceuticals and 4 mentions for Cadrenal Therapeutics. Cadrenal Therapeutics' average media sentiment score of 0.89 beat Shuttle Pharmaceuticals' score of 0.89 indicating that Cadrenal Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Shuttle Pharmaceuticals 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cadrenal Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate EGRX or SHPH?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eagle Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Shuttle Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is EGRX or SHPH more profitable?

Eagle Pharmaceuticals' return on equity of 0.00% beat Shuttle Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Eagle Pharmaceuticals N/A N/A N/A Shuttle Pharmaceuticals N/A -408.34% -138.15%

Do analysts recommend SHPH or IMNN?

Imunon has a consensus price target of $10.00, indicating a potential upside of 446.45%. Given Imunon's stronger consensus rating and higher possible upside, analysts clearly believe Imunon is more favorable than Shuttle Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Shuttle Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Imunon 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation and earnings, SHPH or IMNN?

Imunon is trading at a lower price-to-earnings ratio than Shuttle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Shuttle Pharmaceuticals N/A N/A -$11.72M -$47.70 N/A Imunon N/A N/A -$14.49M -$5.16 N/A

Is SHPH or IMNN more profitable?

Imunon's return on equity of -341.23% beat Shuttle Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Shuttle Pharmaceuticals N/A -408.34% -138.15% Imunon N/A -341.23% -153.79%

Does the media favor SHPH or IMNN?

In the previous week, Shuttle Pharmaceuticals had 5 more articles in the media than Imunon. MarketBeat recorded 6 mentions for Shuttle Pharmaceuticals and 1 mentions for Imunon. Imunon's average media sentiment score of 0.93 beat Shuttle Pharmaceuticals' score of 0.89 indicating that Imunon is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Shuttle Pharmaceuticals 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Imunon 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer SHPH or SYBX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Shuttle Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Synlogic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is SHPH or SYBX more profitable?

Synlogic's return on equity of -26.47% beat Shuttle Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Shuttle Pharmaceuticals N/A -408.34% -138.15% Synlogic N/A -26.47% -18.00%

Does the media prefer SHPH or SYBX?

In the previous week, Shuttle Pharmaceuticals had 5 more articles in the media than Synlogic. MarketBeat recorded 6 mentions for Shuttle Pharmaceuticals and 1 mentions for Synlogic. Shuttle Pharmaceuticals' average media sentiment score of 0.89 beat Synlogic's score of 0.00 indicating that Shuttle Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Shuttle Pharmaceuticals 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Synlogic 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer SHPH or MTVA?

MetaVia has a consensus target price of $20.00, indicating a potential upside of 1,069.59%. Given MetaVia's stronger consensus rating and higher probable upside, analysts plainly believe MetaVia is more favorable than Shuttle Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Shuttle Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 MetaVia 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings & valuation, SHPH or MTVA?

MetaVia is trading at a lower price-to-earnings ratio than Shuttle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Shuttle Pharmaceuticals N/A N/A -$11.72M -$47.70 N/A MetaVia N/A N/A -$12.97M -$5.19 N/A

Is SHPH or MTVA more profitable?

MetaVia's return on equity of -172.92% beat Shuttle Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Shuttle Pharmaceuticals N/A -408.34% -138.15% MetaVia N/A -172.92% -89.39%

Shuttle Pharmaceuticals (SHPH) Competitors

$3.16 -0.39 (-10.99%)

Closing price 07/17/2026 04:00 PM Eastern

Extended Trading

$3.17 +0.01 (+0.44%)

As of 07/17/2026 07:58 PM Eastern

Compare

SHPH vs. CVKD, EGRX, IMNN, SYBX, and MTVA

Should you buy Shuttle Pharmaceuticals stock or one of its competitors? MarketBeat compares Shuttle Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Shuttle Pharmaceuticals include Cadrenal Therapeutics (CVKD), Eagle Pharmaceuticals (EGRX), Imunon (IMNN), Synlogic (SYBX), and MetaVia (MTVA). These companies are all part of the "pharmaceutical products" industry.

How does Shuttle Pharmaceuticals compare to Cadrenal Therapeutics?

Shuttle Pharmaceuticals (NASDAQ:SHPH) and Cadrenal Therapeutics (NASDAQ:CVKD) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, valuation, risk, profitability and institutional ownership.

In the previous week, Shuttle Pharmaceuticals had 2 more articles in the media than Cadrenal Therapeutics. MarketBeat recorded 6 mentions for Shuttle Pharmaceuticals and 4 mentions for Cadrenal Therapeutics. Cadrenal Therapeutics' average media sentiment score of 0.89 beat Shuttle Pharmaceuticals' score of 0.89 indicating that Cadrenal Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Shuttle Pharmaceuticals	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cadrenal Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cadrenal Therapeutics is trading at a lower price-to-earnings ratio than Shuttle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shuttle Pharmaceuticals	N/A	N/A	-$11.72M	-$47.70	N/A
Cadrenal Therapeutics	N/A	N/A	-$13.24M	-$5.63	N/A

Cadrenal Therapeutics has a consensus price target of $13.00, indicating a potential upside of 501.85%. Given Cadrenal Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Cadrenal Therapeutics is more favorable than Shuttle Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shuttle Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cadrenal Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Shuttle Pharmaceuticals has a beta of 0.29, meaning that its stock price is 71% less volatile than the broader market. Comparatively, Cadrenal Therapeutics has a beta of 1.73, meaning that its stock price is 73% more volatile than the broader market.

4.6% of Shuttle Pharmaceuticals shares are held by institutional investors. Comparatively, 7.9% of Cadrenal Therapeutics shares are held by institutional investors. 12.6% of Shuttle Pharmaceuticals shares are held by insiders. Comparatively, 26.1% of Cadrenal Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Shuttle Pharmaceuticals' return on equity of -408.34% beat Cadrenal Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shuttle Pharmaceuticals	N/A	-408.34%	-138.15%
Cadrenal Therapeutics	N/A	-411.03%	-275.61%

Summary

Cadrenal Therapeutics beats Shuttle Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

How does Shuttle Pharmaceuticals compare to Eagle Pharmaceuticals?

Eagle Pharmaceuticals (NASDAQ:EGRX) and Shuttle Pharmaceuticals (NASDAQ:SHPH) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, media sentiment, earnings, institutional ownership, valuation, dividends and profitability.

85.4% of Eagle Pharmaceuticals shares are held by institutional investors. Comparatively, 4.6% of Shuttle Pharmaceuticals shares are held by institutional investors. 28.9% of Eagle Pharmaceuticals shares are held by company insiders. Comparatively, 12.6% of Shuttle Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Eagle Pharmaceuticals' return on equity of 0.00% beat Shuttle Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eagle Pharmaceuticals	N/A	N/A	N/A
Shuttle Pharmaceuticals	N/A	-408.34%	-138.15%

Eagle Pharmaceuticals has higher revenue and earnings than Shuttle Pharmaceuticals. Shuttle Pharmaceuticals is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eagle Pharmaceuticals	$257.55M	0.03	$35.64M	$1.18	0.50
Shuttle Pharmaceuticals	N/A	N/A	-$11.72M	-$47.70	N/A

Eagle Pharmaceuticals has a beta of 0.83, suggesting that its stock price is 17% less volatile than the broader market. Comparatively, Shuttle Pharmaceuticals has a beta of 0.29, suggesting that its stock price is 71% less volatile than the broader market.

In the previous week, Shuttle Pharmaceuticals had 6 more articles in the media than Eagle Pharmaceuticals. MarketBeat recorded 6 mentions for Shuttle Pharmaceuticals and 0 mentions for Eagle Pharmaceuticals. Shuttle Pharmaceuticals' average media sentiment score of 0.89 beat Eagle Pharmaceuticals' score of 0.00 indicating that Shuttle Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Eagle Pharmaceuticals	Neutral
Shuttle Pharmaceuticals	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eagle Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Shuttle Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Eagle Pharmaceuticals beats Shuttle Pharmaceuticals on 9 of the 12 factors compared between the two stocks.

How does Shuttle Pharmaceuticals compare to Imunon?

Shuttle Pharmaceuticals (NASDAQ:SHPH) and Imunon (NASDAQ:IMNN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, risk, institutional ownership, valuation and profitability.

Imunon has a consensus price target of $10.00, indicating a potential upside of 446.45%. Given Imunon's stronger consensus rating and higher possible upside, analysts clearly believe Imunon is more favorable than Shuttle Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shuttle Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Imunon	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Imunon's return on equity of -341.23% beat Shuttle Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shuttle Pharmaceuticals	N/A	-408.34%	-138.15%
Imunon	N/A	-341.23%	-153.79%

4.6% of Shuttle Pharmaceuticals shares are held by institutional investors. Comparatively, 4.5% of Imunon shares are held by institutional investors. 12.6% of Shuttle Pharmaceuticals shares are held by insiders. Comparatively, 2.8% of Imunon shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Imunon is trading at a lower price-to-earnings ratio than Shuttle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shuttle Pharmaceuticals	N/A	N/A	-$11.72M	-$47.70	N/A
Imunon	N/A	N/A	-$14.49M	-$5.16	N/A

In the previous week, Shuttle Pharmaceuticals had 5 more articles in the media than Imunon. MarketBeat recorded 6 mentions for Shuttle Pharmaceuticals and 1 mentions for Imunon. Imunon's average media sentiment score of 0.93 beat Shuttle Pharmaceuticals' score of 0.89 indicating that Imunon is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Shuttle Pharmaceuticals	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Imunon	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Shuttle Pharmaceuticals has a beta of 0.29, meaning that its share price is 71% less volatile than the broader market. Comparatively, Imunon has a beta of 1.96, meaning that its share price is 96% more volatile than the broader market.

Summary

Imunon beats Shuttle Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Shuttle Pharmaceuticals compare to Synlogic?

Shuttle Pharmaceuticals (NASDAQ:SHPH) and Synlogic (NASDAQ:SYBX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shuttle Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Synlogic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Shuttle Pharmaceuticals has higher earnings, but lower revenue than Synlogic. Synlogic is trading at a lower price-to-earnings ratio than Shuttle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shuttle Pharmaceuticals	N/A	N/A	-$11.72M	-$47.70	N/A
Synlogic	$8K	1,071.74	-$23.36M	-$0.06	N/A

Synlogic's return on equity of -26.47% beat Shuttle Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shuttle Pharmaceuticals	N/A	-408.34%	-138.15%
Synlogic	N/A	-26.47%	-18.00%

4.6% of Shuttle Pharmaceuticals shares are owned by institutional investors. Comparatively, 63.4% of Synlogic shares are owned by institutional investors. 12.6% of Shuttle Pharmaceuticals shares are owned by insiders. Comparatively, 2.6% of Synlogic shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Shuttle Pharmaceuticals has a beta of 0.29, suggesting that its stock price is 71% less volatile than the broader market. Comparatively, Synlogic has a beta of 0.54, suggesting that its stock price is 46% less volatile than the broader market.

In the previous week, Shuttle Pharmaceuticals had 5 more articles in the media than Synlogic. MarketBeat recorded 6 mentions for Shuttle Pharmaceuticals and 1 mentions for Synlogic. Shuttle Pharmaceuticals' average media sentiment score of 0.89 beat Synlogic's score of 0.00 indicating that Shuttle Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Shuttle Pharmaceuticals	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Synlogic	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Synlogic beats Shuttle Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

How does Shuttle Pharmaceuticals compare to MetaVia?

Shuttle Pharmaceuticals (NASDAQ:SHPH) and MetaVia (NASDAQ:MTVA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, earnings, risk and valuation.

MetaVia's return on equity of -172.92% beat Shuttle Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shuttle Pharmaceuticals	N/A	-408.34%	-138.15%
MetaVia	N/A	-172.92%	-89.39%

MetaVia has a consensus target price of $20.00, indicating a potential upside of 1,069.59%. Given MetaVia's stronger consensus rating and higher probable upside, analysts plainly believe MetaVia is more favorable than Shuttle Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shuttle Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
MetaVia	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

4.6% of Shuttle Pharmaceuticals shares are owned by institutional investors. Comparatively, 1.4% of MetaVia shares are owned by institutional investors. 12.6% of Shuttle Pharmaceuticals shares are owned by company insiders. Comparatively, 0.6% of MetaVia shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Shuttle Pharmaceuticals had 6 more articles in the media than MetaVia. MarketBeat recorded 6 mentions for Shuttle Pharmaceuticals and 0 mentions for MetaVia. MetaVia's average media sentiment score of 0.96 beat Shuttle Pharmaceuticals' score of 0.89 indicating that MetaVia is being referred to more favorably in the news media.

Company	Overall Sentiment
Shuttle Pharmaceuticals	Positive
MetaVia	Positive

MetaVia is trading at a lower price-to-earnings ratio than Shuttle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shuttle Pharmaceuticals	N/A	N/A	-$11.72M	-$47.70	N/A
MetaVia	N/A	N/A	-$12.97M	-$5.19	N/A

Shuttle Pharmaceuticals has a beta of 0.29, suggesting that its share price is 71% less volatile than the broader market. Comparatively, MetaVia has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market.

Summary

MetaVia beats Shuttle Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

Get Shuttle Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SHPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SHPH vs. The Competition

Export

Metric	Shuttle Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.26M	$3.03B	$6.89B	$12.43B
Dividend Yield	N/A	2.07%	2.67%	8.84%
P/E Ratio	-0.07	19.91	27.14	23.89
Price / Sales	N/A	350.00	524.02	90.49
Price / Cash	N/A	57.21	51.46	60.07
Price / Book	0.28	4.26	10.69	6.18
Net Income	-$11.72M	$65.46M	$3.59B	$331.73M
7 Day Performance	8.22%	-3.17%	-2.18%	-2.04%
1 Month Performance	-8.67%	0.74%	1.63%	-2.14%
1 Year Performance	-91.71%	19.10%	25.56%	17.28%

Shuttle Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SHPH Shuttle Pharmaceuticals	1.0639 of 5 stars	$3.16 -11.0%	N/A	-92.0%	$2.26M	N/A	N/A	5	Gap Down
CVKD Cadrenal Therapeutics	2.7073 of 5 stars	$3.10 -1.9%	$13.00 +319.4%	-81.8%	$8.90M	N/A	N/A	4
EGRX Eagle Pharmaceuticals	N/A	$0.67 flat	N/A	-83.9%	$8.70M	$257.55M	0.57	100	Gap Down
IMNN Imunon	3.3515 of 5 stars	$2.06 +5.6%	$10.00 +385.4%	-79.8%	$8.65M	N/A	N/A	30
SYBX Synlogic	0.0861 of 5 stars	$0.70 -1.5%	N/A	-56.6%	$8.20M	$8K	N/A	80

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SHPH) was last updated on 7/18/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Shuttle Pharmaceuticals (SHPH) Competitors

SHPH vs. CVKD, EGRX, IMNN, SYBX, and MTVA

How does Shuttle Pharmaceuticals compare to Cadrenal Therapeutics?

Summary

How does Shuttle Pharmaceuticals compare to Eagle Pharmaceuticals?

Summary

How does Shuttle Pharmaceuticals compare to Imunon?

Summary

How does Shuttle Pharmaceuticals compare to Synlogic?

Summary

How does Shuttle Pharmaceuticals compare to MetaVia?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SHPH vs. The Competition

Shuttle Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Shuttle Pharmaceuticals (SHPH) Competitors

SHPH vs. CVKD, EGRX, IMNN, SYBX, and MTVA

How does Shuttle Pharmaceuticals compare to Cadrenal Therapeutics?

Does the media favor SHPH or CVKD?

Which has stronger earnings and valuation, SHPH or CVKD?

Do analysts prefer SHPH or CVKD?

Which has more risk & volatility, SHPH or CVKD?

Do insiders & institutionals hold more shares of SHPH or CVKD?

Is SHPH or CVKD more profitable?

Summary

How does Shuttle Pharmaceuticals compare to Eagle Pharmaceuticals?

Do insiders & institutionals hold more shares of EGRX or SHPH?

Is EGRX or SHPH more profitable?

Which has higher valuation and earnings, EGRX or SHPH?

Which has more volatility and risk, EGRX or SHPH?

Does the media refer more to EGRX or SHPH?

Do analysts rate EGRX or SHPH?

Summary

How does Shuttle Pharmaceuticals compare to Imunon?

Do analysts recommend SHPH or IMNN?

Is SHPH or IMNN more profitable?

Do institutionals and insiders have more ownership in SHPH or IMNN?

Which has stronger valuation and earnings, SHPH or IMNN?

Does the media favor SHPH or IMNN?

Which has more risk and volatility, SHPH or IMNN?

Summary

How does Shuttle Pharmaceuticals compare to Synlogic?

Do analysts prefer SHPH or SYBX?

Which has preferable valuation and earnings, SHPH or SYBX?

Is SHPH or SYBX more profitable?

Do institutionals & insiders believe in SHPH or SYBX?

Which has more risk & volatility, SHPH or SYBX?

Does the media prefer SHPH or SYBX?

Summary

How does Shuttle Pharmaceuticals compare to MetaVia?

Is SHPH or MTVA more profitable?

Do analysts prefer SHPH or MTVA?

Do institutionals and insiders believe in SHPH or MTVA?

Does the media prefer SHPH or MTVA?

Which has stronger earnings & valuation, SHPH or MTVA?

Which has more volatility & risk, SHPH or MTVA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SHPH vs. The Competition

Shuttle Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools